{"id":"tp-60675","type":"article-newspaper","title":"Bernstein Downgrades Summit Therapeutics to Underperform on R&D Concerns","author":"Enna Lee","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/investing/60675","datePublished":"2026-11-18T17:29:46.000Z","dateModified":"2026-11-18T17:29:46.000Z","language":"en","abstract":"The FDA declined to approve ivonescimab, Summit’s lead asset developed with partner Akeso in China.","section":"Investing","references":[]}